Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference

Core Viewpoint - Cardiol Therapeutics Inc. is advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease and will present at the TD Cowen 46th Annual Health Care Conference on March 4, 2026 [1][2]. Company Overview - Cardiol Therapeutics Inc. is a late-stage life sciences company focused on therapies for heart disease, with its lead drug candidate, CardiolRx™, targeting inflammation and fibrosis related to conditions such as pericarditis, myocarditis, and heart failure [3]. Clinical Programs - The MAVERIC Program is evaluating CardiolRx™ for recurrent pericarditis, with a completed Phase II study and an ongoing pivotal Phase III trial. The U.S. FDA has granted Orphan Drug Designation for CardiolRx™ in this context [4]. - The ARCHER Program is studying CardiolRx™ in acute myocarditis, a significant cause of heart failure and sudden cardiac death in young adults, with a completed Phase II study assessing safety and efficacy [5]. Additional Developments - The company is also developing CRD-38, a novel subcutaneously administered drug formulation for inflammatory heart disease, including heart failure, which incurs healthcare costs exceeding US$30 billion annually in the U.S. [6].